Notice Information
Notice Title
NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema
Notice Description
National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.
Lot Information
Lot 1 - C1 Esterase - Recombinant IV (acute treatment)
NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 6 - LanadelumabNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 7 - BerotralstatNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 5 - IcatibantNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.
Options: Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months
Lot 1 - C1 Esterase - Recombinant IV (acute treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 6 - LanadelumabNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 7 - BerotralstatNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Lot 5 - IcatibantNHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.
Additional CPV Codes:
33141520 - Plasma Extracts
33141510 - Blood Products
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-0314ad
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/019862-2022
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33141510 - Blood products
33141520 - Plasma extracts
33600000 - Pharmaceutical products
Notice Value(s)
- Tender Value
- £198,666,666 £100M-£1B
- Lots Value
- £7 Under £100K
- Awards Value
- Not specified
- Contracts Value
- £1
Notice Dates
- Publication Date
- 21 Jul 20223 years ago
- Submission Deadline
- 16 Mar 2022Expired
- Future Notice Date
- Not specified
- Award Date
- 19 Jun 20223 years ago
- Contract Period
- 30 Jun 2022 - 31 Dec 2023 1-2 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Active, Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS ENGLAND
- Additional Buyers
THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Contact Name
- Philip Grieve
- Contact Email
- philip.grieve@nhs.net
- Contact Phone
- Not specified
Buyer Location
- Locality
- RUNCORN
- Postcode
- WA7 2ES
- Post Town
- Warrington
- Country
- England
-
- Major Region (ITL 1)
- TLE Yorkshire and The Humber
- Basic Region (ITL 2)
- TLE4 West Yorkshire
- Small Region (ITL 3)
- TLE42 Leeds
- Delivery Location
- Not specified
-
- Local Authority
- Leeds
- Electoral Ward
- Little London & Woodhouse
- Westminster Constituency
- Leeds Central and Headingley
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-0314ad-2022-07-21T11:44:31+01:00",
"date": "2022-07-21T11:44:31+01:00",
"ocid": "ocds-h6vhtk-0314ad",
"description": "RESPONDING TO THIS NOTICE:<br/>Any supplier may be disqualified who does not respond to the following in the requisite manner:<br/>1) Submission of expression of interest and procurement specific information<br/>This procurement exercise will be conducted on the eTendering portal at<br/>https://healthfamily.force.com/s/Welcome<br/>Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:<br/>1.1) If not already registered,Candidates should register on the eTendering portal at<br/>https://health-family.force.com/s/Welcome and click the link to register:<br/>- agree to the user agreement<br/>- populate company details<br/>1.2) Once registered, candidates must register interest as follows:<br/>- log to the portal<br/>- select \"Find Opportunities\" from the supplier home screen, use the \"Sort by:\" facility to find this opportunity and select the bold blue title to select<br/>review opportunity details and click \"Register Interest\"<br/>- as you select the opportunity, you can review documents, send clarification messages,submit the response or decline to respond (if<br/>you decide not to participate in the opportunity)<br/>1.3) There is a supplier user guide on using the system and Candidates can contact the Atamis help desk at supporthealth@atamis.co.uk or by calling 0800 9956035 for technical assistance when completing responses.<br/>2) General supplier information.<br/>To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:<br/>2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page<br/>https://supplierregistration.cabinetoffice.gov.uk and select \"Register\" at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S(r)Number, click on the link at the right of the page to obtain a number from D&B.<br/>Candidates must obtain a Dun & Bradstreet(D&B) D-U-N-S(r) Number to enable registration on the system.<br/>2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise.<br/>D&B data will be supplied automatically by D&B.<br/>2.3) For further help or information concerning this telephone +44 (0) 161 413 7982 or via the message function on the website.<br/>OTHER CONTRACTING AUTHORITIES<br/>The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or<br/>goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare<br/>or health related services.",
"initiationType": "tender",
"tender": {
"id": "CM/PHS/19/5583",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "NHS National Framework Agreement for the Supply of products for the management of Hereditary Angioedema",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
"mainProcurementCategory": "goods",
"description": "National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the invitation to offer documents for a list of the purchasing points.",
"value": {
"amount": 198666666,
"currency": "GBP"
},
"lots": [
{
"id": "Lot 1",
"title": "Lot 1 - C1 Esterase - Recombinant IV (acute treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "Lot 3",
"title": "Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "Lot 6",
"title": "Lot 6 - Lanadelumab",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "Lot 7",
"title": "Lot 7 - Berotralstat",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "Lot 2",
"title": "Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "Lot 4",
"title": "Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "Lot 5",
"title": "Lot 5 - Icatibant",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. The framework will commence on 1 July 2022 for a period of 18 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Please refer to the offer documents for the list of purchasing points.",
"value": {
"amount": 1,
"currency": "GBP"
},
"contractPeriod": {
"startDate": "2022-07-01T00:00:00+01:00",
"endDate": "2023-12-31T23:59:59Z"
},
"hasRenewal": false,
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"hasOptions": true,
"options": {
"description": "Option or Options to extend (at the Authorities sole discretion) for a period or periods up to a total of 48 months"
},
"status": "active"
},
{
"id": "1",
"title": "Lot 1 - C1 Esterase - Recombinant IV (acute treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "3",
"title": "Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "6",
"title": "Lot 6 - Lanadelumab",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "7",
"title": "Lot 7 - Berotralstat",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "2",
"title": "Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend at the Authority's discretion for a period or periods up to a a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "4",
"title": "Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
},
{
"id": "5",
"title": "Lot 5 - Icatibant",
"description": "NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Offer reference number: CM/PHS/19/5583. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents.<br/><br/>Additional CPV Codes:<br/>33141520 - Plasma Extracts<br/>33141510 - Blood Products",
"awardCriteria": {
"criteria": [
{
"name": "Security of Supply",
"type": "quality",
"description": "20%"
},
{
"name": "Ease of Use",
"type": "quality",
"description": "10%"
},
{
"type": "price",
"description": "70%"
}
]
},
"hasOptions": true,
"options": {
"description": "Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months"
},
"status": "cancelled"
}
],
"items": [
{
"id": "Lot 1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 1"
},
{
"id": "Lot 3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 3"
},
{
"id": "Lot 6",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 6"
},
{
"id": "Lot 7",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 7"
},
{
"id": "Lot 2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 2"
},
{
"id": "Lot 4",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 4"
},
{
"id": "Lot 5",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
},
{
"scheme": "CPV",
"id": "33141520",
"description": "Plasma extracts"
},
{
"scheme": "CPV",
"id": "33141510",
"description": "Blood products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England,Scotland,Wales,Northern Ireland,Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "Lot 5"
},
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "1"
},
{
"id": "3",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above"
},
"relatedLot": "3"
},
{
"id": "6",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above"
},
"relatedLot": "6"
},
{
"id": "7",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above"
},
"relatedLot": "7"
},
{
"id": "2",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above"
},
"relatedLot": "2"
},
{
"id": "4",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health & Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of above"
},
"relatedLot": "4"
},
{
"id": "5",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "33600000",
"description": "Pharmaceutical products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "ITT lists Purchasing Points. F/A intended for use by the NHS in England, Scotland, Northern Ireland, Dept of Health and Social Care and Public Health England. F/A may also be used by private sector contractors and agents working on behalf of the above"
},
"relatedLot": "5"
}
],
"submissionMethod": [
"electronicSubmission",
"written"
],
"submissionMethodDetails": "http://health.atamis.co.uk",
"communication": {
"atypicalToolUrl": "http://health.atamis.co.uk"
},
"documents": [
{
"id": "economic",
"documentType": "economicSelectionCriteria"
},
{
"id": "technical",
"documentType": "technicalSelectionCriteria"
}
],
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"techniques": {
"hasFrameworkAgreement": true
},
"coveredBy": [
"GPA"
],
"tenderPeriod": {
"endDate": "2022-03-16T13:00:00Z"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"endDate": "2022-06-14T23:59:59+01:00"
}
},
"awardPeriod": {
"startDate": "2022-03-16T13:00:00Z"
},
"bidOpening": {
"date": "2022-03-16T13:00:00Z",
"address": {
"streetAddress": "Runcorn"
},
"description": "Commercial Medicines Unit Employee"
},
"hasRecurrence": false,
"contractTerms": {
"hasElectronicOrdering": true,
"electronicInvoicingPolicy": "allowed",
"hasElectronicPayment": true
},
"amendments": [
{
"id": "1",
"unstructuredChanges": [
{
"oldValue": {
"text": "UKE"
},
"newValue": {
"text": "UK"
},
"where": {
"section": "I.1.5",
"label": "NUTS code"
}
}
]
}
]
},
"parties": [
{
"id": "GB-FTS-2505",
"name": "The NHS Commissioning Board (operating under the name of NHS England)",
"identifier": {
"legalName": "The NHS Commissioning Board (operating under the name of NHS England)"
},
"address": {
"streetAddress": "2nd Floor, Rutland House",
"locality": "Runcorn",
"region": "UK",
"postalCode": "WA7 2ES",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Philip Grieve",
"email": "philip.grieve@nhs.net",
"url": "http://health.atamis.co.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.england.nhs.uk/",
"buyerProfile": "https://www.england.nhs.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "MINISTRY",
"description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-497",
"name": "The High Court",
"identifier": {
"legalName": "The High Court"
},
"address": {
"streetAddress": "Strand",
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom"
},
"contactPoint": {
"email": "generaloffice@administrativecourtoffice.justice.gov.uk"
},
"roles": [
"reviewBody"
],
"details": {
"url": "https://www.gov.uk/courts-tribunals"
}
},
{
"id": "GB-FTS-3717",
"name": "NHS England",
"identifier": {
"legalName": "NHS England"
},
"address": {
"streetAddress": "Quarry House",
"locality": "Leeds",
"region": "UKE",
"postalCode": "LS2 7UE",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Philip Grieve",
"email": "philip.grieve@nhs.net"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.england.nhs.uk//",
"buyerProfile": "https://www.england.nhs.uk//",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "MINISTRY",
"description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-59321",
"name": "Pharming Group",
"identifier": {
"legalName": "Pharming Group"
},
"address": {
"streetAddress": "Darwinweg, The Netherlands",
"locality": "Darwinweg",
"region": "UK",
"postalCode": "242333",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-57450",
"name": "Takeda UK Ltd",
"identifier": {
"legalName": "Takeda UK Ltd"
},
"address": {
"streetAddress": "1 Kingdom Street",
"locality": "London",
"region": "UK",
"postalCode": "W2 6BD",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-59322",
"name": "BioCryst Ireland Limited",
"identifier": {
"legalName": "BioCryst Ireland Limited"
},
"address": {
"streetAddress": "Harcourt Centre, Harcourt Road",
"locality": "Dublin",
"region": "UK",
"postalCode": "2D02 HW77",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme"
}
},
{
"id": "GB-FTS-57449",
"name": "CSL Behring UK Ltd",
"identifier": {
"legalName": "CSL Behring UK Ltd"
},
"address": {
"streetAddress": "4 Milton Road, Haywards Heath",
"locality": "Haywards Heath",
"region": "UK",
"postalCode": "RH16 1AH",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-59323",
"name": "Martindale Pharma",
"identifier": {
"legalName": "Martindale Pharma"
},
"address": {
"streetAddress": "Building A2 Glory Park, Glory Park Avenue",
"locality": "Wooburn Green",
"region": "UK",
"postalCode": "HP10 0DF",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-59324",
"name": "Piramal Critical care Limited",
"identifier": {
"legalName": "Piramal Critical care Limited"
},
"address": {
"streetAddress": "Suite 4, Heathrow Boulevard",
"locality": "West Drayton",
"region": "UK",
"postalCode": "UB7 0DQ",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme"
}
},
{
"id": "GB-FTS-4224",
"name": "Wockhardt UK Limited",
"identifier": {
"legalName": "Wockhardt UK Limited"
},
"address": {
"streetAddress": "Ash Road North, Wrexham Industrial Estate",
"locality": "Wrexham",
"region": "UK",
"postalCode": "LL13 9UF",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme"
}
},
{
"id": "GB-FTS-59325",
"name": "Cipla",
"identifier": {
"legalName": "Cipla"
},
"address": {
"streetAddress": "Bourne Business Park, Addlestone",
"locality": "Addlestone",
"region": "UK",
"postalCode": "KT15 2LE",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-4177",
"name": "Accord-UK Ltd",
"identifier": {
"legalName": "Accord-UK Ltd"
},
"address": {
"streetAddress": "Whiddon Valley",
"locality": "Barnstaple",
"region": "UK",
"postalCode": "EX32 8NS",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-59326",
"name": "Celix Pharma Ltd.",
"identifier": {
"legalName": "Celix Pharma Ltd."
},
"address": {
"streetAddress": "4 Cullera Close",
"locality": "Middlesex",
"region": "UK",
"postalCode": "HA6 3SE",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "sme"
}
}
],
"buyer": {
"id": "GB-FTS-3717",
"name": "NHS England"
},
"language": "en",
"awards": [
{
"id": "019699-2022-CM/PHS/19/5583-1",
"title": "Hereditary Angioedema. Lot 1 - C1 Esterase - Recombinant IV (acute treatment)",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-59321",
"name": "Pharming Group"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-2",
"relatedLots": [
"3"
],
"title": "Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-57450",
"name": "Takeda UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-3",
"relatedLots": [
"6"
],
"title": "Hereditary Angioedema. Lot 6 - Lanadelumab",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-57450",
"name": "Takeda UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-4",
"relatedLots": [
"7"
],
"title": "Hereditary Angioedema. Lot 7 - Berotralstat",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-59322",
"name": "BioCryst Ireland Limited"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-5",
"title": "Hereditary Angioedema. Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-57449",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-6",
"title": "Hereditary Angioedema. Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-57450",
"name": "Takeda UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-7",
"relatedLots": [
"4"
],
"title": "Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-57449",
"name": "CSL Behring UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-8",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-59323",
"name": "Martindale Pharma"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-9",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-59324",
"name": "Piramal Critical care Limited"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-10",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-4224",
"name": "Wockhardt UK Limited"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-11",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-59325",
"name": "Cipla"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-12",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-57450",
"name": "Takeda UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-13",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-4177",
"name": "Accord-UK Ltd"
}
]
},
{
"id": "019699-2022-CM/PHS/19/5583-14",
"relatedLots": [
"5"
],
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-59326",
"name": "Celix Pharma Ltd."
}
]
}
],
"contracts": [
{
"id": "019699-2022-CM/PHS/19/5583-1",
"awardID": "019699-2022-CM/PHS/19/5583-1",
"title": "Hereditary Angioedema. Lot 1 - C1 Esterase - Recombinant IV (acute treatment)",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-2",
"awardID": "019699-2022-CM/PHS/19/5583-2",
"title": "Lot 3 - C1 Esterase - Plasma derived IV (prophylaxis treatment)",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-3",
"awardID": "019699-2022-CM/PHS/19/5583-3",
"title": "Hereditary Angioedema. Lot 6 - Lanadelumab",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-4",
"awardID": "019699-2022-CM/PHS/19/5583-4",
"title": "Hereditary Angioedema. Lot 7 - Berotralstat",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-5",
"awardID": "019699-2022-CM/PHS/19/5583-5",
"title": "Hereditary Angioedema. Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-6",
"awardID": "019699-2022-CM/PHS/19/5583-6",
"title": "Hereditary Angioedema. Lot 2 - C1 Esterase - Plasma derived IV (acute treatment)",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-7",
"awardID": "019699-2022-CM/PHS/19/5583-7",
"title": "Lot 4 - C1 Esterase - Plasma derived Subcut (prophylaxis treatment)",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-8",
"awardID": "019699-2022-CM/PHS/19/5583-8",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-9",
"awardID": "019699-2022-CM/PHS/19/5583-9",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-10",
"awardID": "019699-2022-CM/PHS/19/5583-10",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-11",
"awardID": "019699-2022-CM/PHS/19/5583-11",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-12",
"awardID": "019699-2022-CM/PHS/19/5583-12",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-13",
"awardID": "019699-2022-CM/PHS/19/5583-13",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
},
{
"id": "019699-2022-CM/PHS/19/5583-14",
"awardID": "019699-2022-CM/PHS/19/5583-14",
"title": "Hereditary Angioedema. Lot 5 - Icatibant",
"status": "active",
"value": {
"amount": 1,
"currency": "GBP"
},
"dateSigned": "2022-06-20T00:00:00+01:00"
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"value": 1
},
{
"id": "6",
"measure": "bids",
"relatedLot": "3",
"value": 1
},
{
"id": "11",
"measure": "bids",
"relatedLot": "6",
"value": 1
},
{
"id": "16",
"measure": "bids",
"relatedLot": "7",
"value": 1
},
{
"id": "21",
"measure": "bids",
"value": 2
},
{
"id": "26",
"measure": "bids",
"value": 2
},
{
"id": "31",
"measure": "bids",
"relatedLot": "4",
"value": 1
},
{
"id": "36",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "41",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "46",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "51",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "56",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "61",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "66",
"measure": "bids",
"relatedLot": "5",
"value": 10
},
{
"id": "2",
"measure": "smeBids",
"value": 0
},
{
"id": "7",
"measure": "smeBids",
"relatedLot": "3",
"value": 0
},
{
"id": "12",
"measure": "smeBids",
"relatedLot": "6",
"value": 0
},
{
"id": "17",
"measure": "smeBids",
"relatedLot": "7",
"value": 1
},
{
"id": "22",
"measure": "smeBids",
"value": 0
},
{
"id": "27",
"measure": "smeBids",
"value": 0
},
{
"id": "32",
"measure": "smeBids",
"relatedLot": "4",
"value": 0
},
{
"id": "37",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "42",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "47",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "52",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "57",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "62",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "67",
"measure": "smeBids",
"relatedLot": "5",
"value": 4
},
{
"id": "3",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "8",
"measure": "foreignBidsFromEU",
"relatedLot": "3",
"value": 0
},
{
"id": "13",
"measure": "foreignBidsFromEU",
"relatedLot": "6",
"value": 0
},
{
"id": "18",
"measure": "foreignBidsFromEU",
"relatedLot": "7",
"value": 1
},
{
"id": "23",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "28",
"measure": "foreignBidsFromEU",
"value": 0
},
{
"id": "33",
"measure": "foreignBidsFromEU",
"relatedLot": "4",
"value": 0
},
{
"id": "38",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "43",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "48",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "53",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "58",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "63",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "68",
"measure": "foreignBidsFromEU",
"relatedLot": "5",
"value": 0
},
{
"id": "4",
"measure": "foreignBidsFromNonEU",
"value": 1
},
{
"id": "9",
"measure": "foreignBidsFromNonEU",
"relatedLot": "3",
"value": 1
},
{
"id": "14",
"measure": "foreignBidsFromNonEU",
"relatedLot": "6",
"value": 1
},
{
"id": "19",
"measure": "foreignBidsFromNonEU",
"relatedLot": "7",
"value": 0
},
{
"id": "24",
"measure": "foreignBidsFromNonEU",
"value": 2
},
{
"id": "29",
"measure": "foreignBidsFromNonEU",
"value": 2
},
{
"id": "34",
"measure": "foreignBidsFromNonEU",
"relatedLot": "4",
"value": 1
},
{
"id": "39",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "44",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "49",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "54",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "59",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "64",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "69",
"measure": "foreignBidsFromNonEU",
"relatedLot": "5",
"value": 10
},
{
"id": "5",
"measure": "electronicBids",
"value": 1
},
{
"id": "10",
"measure": "electronicBids",
"relatedLot": "3",
"value": 1
},
{
"id": "15",
"measure": "electronicBids",
"relatedLot": "6",
"value": 1
},
{
"id": "20",
"measure": "electronicBids",
"relatedLot": "7",
"value": 1
},
{
"id": "25",
"measure": "electronicBids",
"value": 2
},
{
"id": "30",
"measure": "electronicBids",
"value": 2
},
{
"id": "35",
"measure": "electronicBids",
"relatedLot": "4",
"value": 1
},
{
"id": "40",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
},
{
"id": "45",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
},
{
"id": "50",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
},
{
"id": "55",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
},
{
"id": "60",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
},
{
"id": "65",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
},
{
"id": "70",
"measure": "electronicBids",
"relatedLot": "5",
"value": 10
}
]
}
}